UroGen Pharma Ltd Net Assets
UroGen Pharma Ltd net assets. Based on the latest financial reports, UroGen Pharma Ltd (URGN) has net assets worth $-132.40 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($252.59 Million) and total liabilities ($384.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore UroGen Pharma Ltd (URGN) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-132.40 Million |
| % of Total Assets | -52.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -1353.7% |
| 10-Year Change | -746.8% |
| Growth Volatility | 423.0 |
Net Assets of UroGen Pharma Ltd (2013–2025)
Net assets of UroGen Pharma Ltd from 2013 to 2025. This chart illustrates how UroGen Pharma Ltd's net assets have evolved over time, based on quarterly financial data. See URGN net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for UroGen Pharma Ltd (2013–2025)
The table below shows the annual net assets of UroGen Pharma Ltd from 2013 to 2025. For live market cap and overall valuation, see UroGen Pharma Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-105.47 Million | -1098.16% |
| 2024-12-31 | $-8.80 Million | +86.50% |
| 2023-12-31 | $-65.21 Million | +27.02% |
| 2022-12-31 | $-89.36 Million | -1162.18% |
| 2021-12-31 | $8.41 Million | -91.27% |
| 2020-12-31 | $96.36 Million | -46.56% |
| 2019-12-31 | $180.30 Million | +100.13% |
| 2018-12-31 | $90.09 Million | +31.50% |
| 2017-12-31 | $68.52 Million | +320.16% |
| 2016-12-31 | $16.31 Million | -4.93% |
| 2015-12-31 | $17.15 Million | +394.61% |
| 2014-12-31 | $3.47 Million | +26.52% |
| 2013-12-31 | $2.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to UroGen Pharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 95160800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
UroGen Pharma Ltd Net Assets Breakdown (December 2025)
UroGen Pharma Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $133.00K | % |
| Other Comprehensive Income | $19.00K | % |
| Other Components | $854.09 Million | % |
| Total Equity | $-105.47 Million | 100.00% |
UroGen Pharma Ltd Competitors by Market Cap
The table below lists competitors of UroGen Pharma Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zotye Automobile Co Ltd
SHE:000980
|
$1.21 Billion |
|
United Corporations Limited
TO:UNC
|
$1.21 Billion |
|
Shenzhen Zhenye Group Co Ltd
SHE:000006
|
$1.21 Billion |
|
Inox Wind Limited
NSE:INOXWIND
|
$1.21 Billion |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
$1.21 Billion |
|
Forestar Group Inc
NYSE:FOR
|
$1.21 Billion |
|
PagSeguro Digital Ltd
NYSE:PAGS
|
$1.21 Billion |
|
Universal Insurance Holdings Inc
NYSE:UVE
|
$1.21 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in UroGen Pharma Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -8,803,000 to -105,474,000, a change of -96,671,000.
- Net loss of 153,494,000 reduced equity.
- New share issuances of 39,801,000 increased equity.
- Other comprehensive income decreased equity by 37,000.
- Other factors increased equity by 17,059,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-153.49 Million | -145.53% |
| Share Issuances | $39.80 Million | +37.74% |
| Other Comprehensive Income | $-37.00K | -0.04% |
| Other Changes | $17.06 Million | +16.17% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares UroGen Pharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $1.29 | $24.75 | x |
| 2014-12-31 | $1.51 | $24.75 | x |
| 2015-12-31 | $7.45 | $24.75 | x |
| 2016-12-31 | $1.36 | $24.75 | x |
| 2017-12-31 | $7.05 | $24.75 | x |
| 2018-12-31 | $5.72 | $24.75 | x |
| 2019-12-31 | $8.78 | $24.75 | x |
| 2020-12-31 | $4.42 | $24.75 | x |
| 2021-12-31 | $0.38 | $24.75 | x |
| 2022-12-31 | $-3.92 | $24.75 | x |
| 2023-12-31 | $-2.26 | $24.75 | x |
| 2024-12-31 | $-0.21 | $24.75 | x |
| 2025-12-31 | $-2.19 | $24.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently UroGen Pharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -139.81%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-150.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -120.61% | 0.00% | 0.00x | 1.18x | $-3.58 Million |
| 2014 | -131.40% | 0.00% | 0.00x | 1.26x | $-4.90 Million |
| 2015 | -73.98% | 0.00% | 0.00x | 1.13x | $-14.40 Million |
| 2016 | -11.90% | -11.07% | 0.76x | 1.41x | $-3.57 Million |
| 2017 | -29.19% | -245.16% | 0.11x | 1.10x | $-26.85 Million |
| 2018 | -83.98% | -6707.18% | 0.01x | 1.15x | $-84.67 Million |
| 2019 | -58.32% | -584144.44% | 0.00x | 1.12x | $-123.18 Million |
| 2020 | -133.34% | -1088.94% | 0.10x | 1.27x | $-138.12 Million |
| 2021 | -1317.25% | -230.67% | 0.40x | 14.23x | $-111.66 Million |
| 2022 | 0.00% | -170.58% | 0.47x | 0.00x | $-100.85 Million |
| 2023 | 0.00% | -123.61% | 0.46x | 0.00x | $-95.72 Million |
| 2024 | 0.00% | -140.35% | 0.32x | 0.00x | $-125.99 Million |
| 2025 | 0.00% | -139.81% | 0.55x | 0.00x | $-142.95 Million |
Industry Comparison
This section compares UroGen Pharma Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $150,779,214
- Average return on equity (ROE) among peers: -66.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| UroGen Pharma Ltd (URGN) | $-132.40 Million | -120.61% | N/A | $1.21 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $25.47 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $14.83 Million | -365.49% | 3.32x | $238.46 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $16.14 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $724.08 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $25.82 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $7.48 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more